» Articles » PMID: 18213632

The Metabolites Citrate, Myo-inositol, and Spermine Are Potential Age-independent Markers of Prostate Cancer in Human Expressed Prostatic Secretions

Overview
Journal Prostate
Date 2008 Jan 24
PMID 18213632
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Due to specific physiological functions, prostatic tissues and fluids have unique metabolic profiles. In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS).

Methods: Metabolic profiles of EPS from 52 men with PCa and from 26 healthy controls were analyzed using quantitative (1)H-NMRS. The metabolites quantified included citrate, spermine, myo-inositol, lactate, alanine, phosphocholine, glutamine, acetate, and hydroxybutyrate. Logistic regression (LR) was used to model the risk of PCa based on metabolite concentrations while adjusting for age.

Results: The average age of the EPS donors with PCa was 58.0+/-7.0 years and 52.2+/-12.1 for the healthy donors. The median Gleason score for the men with PCa was 7 (range 5-9). The LR models indicated that the absolute concentrations of citrate, myo-inositol, and spermine were highly predictive of PCa and inversely related to the risk of PCa. The areas under the receiver operating characteristic curves (AUROC) for citrate, myo-inositol and spermine were 0.89, 0.87, and 0.79, respectively. At 90% sensitivity, these metabolites had specificities of 74%, 51%, and 34%, respectively. The LR analysis indicated that absolute levels of these three metabolites were independent of age.

Conclusions: The results indicate that citrate, myo-inositol and spermine are potentially important markers of PCa in human EPS. Further, the absolute concentrations of these metabolites in EPS appear to be independent of age, increasing the potential utility of these markers due to elimination of age as a confounding variable.

Citing Articles

The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.

Tamarindo G, Ribeiro C, Silva A, Castro A, Caruso I, Souza F Cancer Metab. 2024; 12(1):24.

PMID: 39113152 PMC: 11308158. DOI: 10.1186/s40170-024-00348-0.


Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.

Ambrosini G, Cordani M, Zarrabi A, Alcon-Rodriguez S, Sainz R, Velasco G Cell Commun Signal. 2024; 22(1):36.

PMID: 38216942 PMC: 10790277. DOI: 10.1186/s12964-023-01462-0.


Multiplatform Metabolomics Studies of Human Cancers With NMR and Mass Spectrometry Imaging.

Zhong A, Muti I, Eyles S, Vachet R, Sikora K, Bobst C Front Mol Biosci. 2022; 9:785232.

PMID: 35463966 PMC: 9024335. DOI: 10.3389/fmolb.2022.785232.


Developments in proton MR spectroscopic imaging of prostate cancer.

Stamatelatou A, Scheenen T, Heerschap A MAGMA. 2022; 35(4):645-665.

PMID: 35445307 PMC: 9363347. DOI: 10.1007/s10334-022-01011-9.


Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer.

Ravikanth Reddy R, Jagannathan N Indian J Urol. 2022; 38(2):99-109.

PMID: 35400867 PMC: 8992727. DOI: 10.4103/iju.iju_416_21.